Mesenchymal stem cell therapy (Medipost)

间充质干细胞疗法（Medipost）

Report date: 2023/01/12 15:47:52

Base Information

Drug NameMesenchymal stem cell therapy (Medipost)

Drug Alias NameBonestemHeartstemPromostem

ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapyCell and gene therapy > Cell therapy > Source of cells > Umbilical cord-derived

Mechanisms of ActionCell replacements

TargetsNot applicable

Therapy Area/IndicationsGraft vs Host DiseaseLeukemia

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesMedipost Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesMedipost Co Ltd

Active IndicationsN/A

Inactive IndicationsGraft vs Host DiseaseLeukemia

Other Information

ATC CodeN/A